Roadmap for cardiovascular prevention trials in chronic kidney disease

The Lancet

Volumn 388, Issue 10055, 2016, Pages 1964-1966

  Rossignol, Patrick ^a,b,c   Pitt, Bertram ^d   Thompson, Aliza ^e   Zannad, Faiez ^a,b  

^a UNIVERSITÉ DE LORRAINE   (France)

^b F CRIN INI CRCT (Cardiovascular and Renal Clinical Trialists)   (France)

^c Association Lorraine Pour le Traitement de l'Insuffisance Ré Nale   (France)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CHOLESTEROL; TROPONIN;

ACUTE CORONARY SYNDROME; ADVERSE OUTCOME; ALBUMINURIA; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); CONCENTRATION PROCESS; DRUG APPROVAL; END STAGE RENAL DISEASE; EVIDENCE BASED PRACTICE; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEMODIALYSIS; HOSPITAL ADMISSION; HUMAN; HYPERVOLEMIA; KIDNEY FUNCTION; MEDICARE; MORTALITY RATE; NEOPLASM; NOTE; OUTCOME ASSESSMENT; PATIENT SAFETY; PREVENTION STUDY; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; SEPSIS; SUDDEN DEATH; SURVIVAL RATE; UNSTABLE ANGINA PECTORIS; CARDIOVASCULAR DISEASES; CHRONIC KIDNEY FAILURE; COMPLICATION;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84992618639     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)31331-9     Document Type: Note

References (12)

1. 1 Gansevoort, RT, Correa-Rotter, R, Hemmelgarn, BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382 (2013), 339–352.
2. 2 Ortiz, A, Covic, A, Fliser, D, et al. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 383 (2014), 1831–1843.
3. 3 Konstantinidis, I, Nadkarni, GN, Yacoub, R, et al. Representation of patients with kidney disease in trials of cardiovascular interventions: an updated systematic review. JAMA Intern Med 176 (2016), 121–124.
4. 4 Zannad, F, Kessler, M, Lehert, P, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 70 (2006), 1318–1324.
5. 5 Fellstrom, BC, Jardine, AG, Schmieder, RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360 (2009), 1395–1407.
6. 6 Rossignol, P, Cridlig, J, Lehert, P, Kessler, M, Zannad, F, Visit-to-visit blood pressure variability is a strong predictor of cardiovascular events in hemodialysis: insights from FOSIDIAL. Hypertension 60 (2012), 339–346.
7. 7 Hicks, KA, Tcheng, JE, Bozkurt, B, et al. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). Circulation 132 (2015), 302–361.
8. 8 Sandoval, Y, Herzog, CA, Love, SA, et al. Prognostic value of serial changes in high-sensitivity cardiac troponin I and T over 3 months using reference change values in hemodialysis patients. Clin Chem 62 (2016), 631–638.
9. 9 Badiou, S, Boudet, A, Leray-Moragues, H, et al. Monthly reference change value of cardiac troponin in hemodialysis patients as a useful tool for long-term cardiovascular management. Clin Biochem, 2016, 10.1016/j.clinbiochem.2016.05.015 published online May 20.
10. 10 Green, D, Roberts, PR, New, DI, Kalra, PA, Sudden cardiac death in hemodialysis patients: an in-depth review. Am J Kidney Dis 57 (2011), 921–929.
11. 11 United States Renal Data System, United States Renal Data System. 2015 USRDS annual data report: epidemiology of kidney disease in the United States, 2015, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA.
12. 12 Vanholder, R, Fouque, D, Glorieux, G, et al. Clinical management of the uraemic syndrome in chronic kidney disease. Lancet Diabetes Endocrinol 4 (2016), 360–373.